Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

311
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
311
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

528
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
528
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

509
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
509
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

404
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
404
Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers01:25

Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers

515
β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but...
515
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

375
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
375

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Identification, reliability, and validity of drug-drug interaction checkers in chronic diseases: A systematic review.

British journal of pharmacology·2026
Same author

Beta-blocker therapy after myocardial infarction: an umbrella review.

EClinicalMedicine·2026
Same author

Higher internal locus of control is associated with higher performance in a workplace walking intervention, Global Corporate Challenge®.

PloS one·2026
Same author

Assessing community resilience during the first COVID-19 wave peak in a megacity in eastern China: a cross-sectional study using social media data.

BMJ open·2026
Same author

Walking and Health Outcomes in Older Adults: A Systematic Review and Meta-Analysis of Longitudinal Studies.

American journal of health promotion : AJHP·2026
Same author

Cardiovascular-Related Polypharmacy and Its Association with Liver and Kidney Function: A Cross-Sectional Study Using Primary Care Data.

Drugs & aging·2026

Related Experiment Video

Updated: May 30, 2025

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy
07:40

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy

Published on: May 26, 2023

1.1K

Beta-Blocker Therapy After Myocardial Infarction.

Pilar Cataldo Miranda1, Danijela Gasevic2, Caroline Trin1

  • 1School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.

JACC. Advances
|January 31, 2025
PubMed
Summary

Beta-blocker therapy after myocardial infarction (MI) shows diminishing benefits, especially in patients with preserved ejection fraction. Further research is needed to define its role in modern MI management.

Keywords:
CVDbeta-blockersmyocardial infarction

More Related Videos

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
14:35

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Published on: April 17, 2021

8.4K
A Modified Simple Method for Induction of Myocardial Infarction in Mice
04:29

A Modified Simple Method for Induction of Myocardial Infarction in Mice

Published on: December 3, 2021

3.5K

Related Experiment Videos

Last Updated: May 30, 2025

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy
07:40

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy

Published on: May 26, 2023

1.1K
Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
14:35

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Published on: April 17, 2021

8.4K
A Modified Simple Method for Induction of Myocardial Infarction in Mice
04:29

A Modified Simple Method for Induction of Myocardial Infarction in Mice

Published on: December 3, 2021

3.5K

Area of Science:

  • Cardiology
  • Clinical Medicine
  • Pharmacotherapy

Background:

  • Historically, beta-blockers were foundational for post-myocardial infarction (MI) care, significantly reducing mortality and morbidity.
  • Evolving treatment strategies for MI patients have raised questions about the continued universal benefit of beta-blocker therapy.
  • Current evidence challenges the effectiveness of beta-blockers in specific patient subgroups, such as those with preserved left ventricular ejection fraction.

Purpose of the Study:

  • To review and compare major studies on beta-blocker therapy in myocardial infarction (MI) from historical to contemporary practice.
  • To evaluate the impact of beta-blockers on various health outcomes in the context of evolving MI treatments.
  • To identify gaps in knowledge and emphasize the need for further research on beta-blocker therapy's current role in post-MI management.

Main Methods:

  • Systematic review and comparative analysis of influential studies.
  • Inclusion of research spanning the prereperfusion era to modern therapeutic practices.
  • Focus on studies examining diverse health outcomes related to beta-blocker use post-MI.

Main Results:

  • The apparent benefits of beta-blocker therapy post-MI are less clear with contemporary treatments.
  • Effectiveness is particularly questioned in patients with preserved left ventricular ejection fraction.
  • Contemporary guidelines show variability in recommendations for beta-blocker use in post-MI patients.

Conclusions:

  • The role of beta-blocker therapy in post-myocardial infarction (MI) management requires re-evaluation.
  • Evidence suggests a potential decline in benefits, especially in specific patient populations.
  • Further research is crucial to establish optimal, evidence-based guidelines for beta-blocker use in current MI care.